Combining Serum Prostate Health Index With Urinary PCA3 and TMPRSS2:ERG RNA Testing Improves Detection of Clinically Significant Prostate Cancer
Combining serum Phi with urinary PCA3 RNA alone or together with urinary T2:ERG RNA, simultaneously or sequentially, improves selection of men for initial prostate biopsy and represents an avenue to improve early detection of aggressive PCa.
Authors
- Lori J. Sokoll (ORCID: https://orcid.org/0000-0001-5130-0060)
- Nicholas W. Eyrich (ORCID: https://orcid.org/0000-0003-4247-0759)
- Y. Huang
- D. Lin
- Y. Lotan
- Douglas Scherr (ORCID: https://orcid.org/0000-0002-0008-0771)
- Vivek Narayan (ORCID: https://orcid.org/0000-0002-8205-738X)
- Mo Bidair
- Martin G. Sanda
- Arul Chinnaiyan
- Dattatraya Patil
- Ian M. Thompson
- Daniel W. Chan
- Yanqing Wang
- John Wei
- Samir S. Taneja
- Scott A. Tomlins
- Adam Kibel
- Yingye Zheng
Institutions
- Brigham and Women's Hospital (US)
- Johns Hopkins University (US)
- Emory University (US)
- The University of Texas at San Antonio Health Science Center (US)
- Georgia State University (US)
- University of Washington (US)
- Cornell University (US)
- University of Michigan (US)
- Johns Hopkins Medicine (US)
- Fred Hutch Cancer Center (US)
- Los Angeles Clinical Trials (US)
- New York University (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- JU Open Plus
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1097/ju9.0000000000000425
- Citations
- 2
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 72.89
Funders
- National Institutes of Health
- National Cancer Institute